Q-omics provides the consensus-scored FAM104B profile across patient tissues and cancer cell-line models. FAM104B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM104B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, FAM104B RNA expression shows 18,309 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, and UVM as cancer lineages where FAM104B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM104B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM104B survival associations across molecular data types. FAM104B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM104B RNA expression–survival associations across cancer types. High FAM104B expression shows unfavorable associations in KICH, LIHC and UVM, but favorable associations in LUSC, ACC and OV. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for FAM104B RNA expression.
This table summarizes FAM104B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM104B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM104B shows lower tumor expression in KICH, THCA, KIRC, LUAD and UCEC and higher tumor expression in LIHC. The KICH box plot shows higher FAM104B RNA expression in normal versus tumor tissue (log2 FC = −2.034, t-test p < 0.001).
This table shows molecular features associated with FAM104B in patient tissues and cancer cell lines. In patient samples, FAM104B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM104B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
